# SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding

> **NCT04478019** · EARLY_PHASE1 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 245 (actual)

## Conditions studied

- COVID-19
- SARS-CoV 2

## Interventions

- **DRUG:** 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse

## Key facts

- **NCT ID:** NCT04478019
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-07
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 245 (ACTUAL)
- **Last updated:** 2022-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04478019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04478019, "SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04478019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*